Esophageal Cancer Market Overview

Rated the sixth most common type of cancer affecting patients, esophageal cancer is responsible for numerus deaths worldwide. Tobacco and alcohol consumption, or certain dietary habits can lead to probabilities of attaining the disease. With advances in treatment, diagnostics, and surgical techniques, the prognosis rate of esophageal cancer has improved considerably over the ears. In addition, increase in survival rates, detection at an early stage, and transformation in the field of drug development have all worked in favor of the global esophageal cancer market.

Cancer is one of the leading causes of death worldwide and is expected to witness the expansion of patient population in the years to come. One of the types of cancer that affect the food pipe connecting the mouth and stomach is the esophageal cancer which is majorly prevalent among the older adults belonging to 55 years and above age group. Market Research Future (MRFR) has found out that Esophageal Cancer Market is projected to reach USD 22 billion at CAGR of 8.22% by 2030.

Historically, esophageal cancer had limited treatment options. However, recent treatment advances are aiding patients to opt for treatment options that can possibly help them live longer with less side effects. Intensive RD activities and clinical trials are being carried out at an accelerated pace. Combination of various therapies such as chemotherapy with immunotherapy have demonstrated significant improvement in response rates. Of late, the FDA has also been approving more immunotherapy drugs for a variety of oncological disorders, which is likely to uplift the development of the esophageal cancer market.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/3280

Esophageal Cancer Market Segmentation

By type, the global esophageal cancer market has been segmented into esophageal squamous-cell carcinoma, esophageal adenocarcinoma, and others.

On the basis of phase, the esophageal cancer market has been segmented into phase I, phases II, and phases III.

The esophageal cancer market by treatment, has been segmented into surgery, chemotherapy and radiotherapy and other.

Esophageal Cancer Market Regional Analysis

Region-wise, the esophageal cancer market has been segmented into North America, the Middle East Africa (MEA), Asia Pacific (APAC), and Europe.

With numerous cases of esophageal cancer, North America has commanded the leading position in the global esophageal cancer market. The population of the region is highly addicted to tobacco, which remains among the prime causes of esophageal cancer. High government support, high healthcare expenditure, and favorable reimbursement landscape is providing impetus to the growth of the North America market. The US has major contribution to make in the North America market. Robust healthcare infrastructure and the presence of a wide population base supports the growth of the market.

Intensive RD activities in Europe is driving the growth of the esophageal cancer market in Europe. The expansion of the APAC market can be attributed to the surging incidence rate of esophageal cancer and large unmet needs in the region.

Competitive Landscape

Amgen Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), Johnson Johnson (U.S.), Eli Lilly and Company (U.S.), Merck Co., Inc. (U.S.), F. Hoffmann-La Roche (Switzerland), Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K), Bristol-Myers Squibb (U.S.), Bristol-Myers Squibb Company (U.S.), and Gilead Sciences, Inc. (U.S.) are the eminent players in the global esophageal cancer market.

Industry Updates

August 2019 - A new immunotherapy drug has been approved by the U.S. Food and Drug Administration (FDA) aimed at treating esophageal cancer. Dubbed as “Keytruda", the new immunotherapy drug pembrolizumab has exhibited its efficiency in reducing the risk of fatality in esophageal cancer patients by 31% in clinical trials. The treatment would be beneficial for those patients who are unresponsive to chemotherapy. Keytruda is the result of aggressive RD by the leading pharmaceutical company, Merck Co.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/esophageal-cancer-market-3280

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com